United States Anti-Inflammatory Drugs Market Insight
Published: 27 May 2026 | Report Format: Electronic (PDF)
The forecasted growth rate for the United States anti-inflammatory drug market is 6.82%, and this is estimated based on factors such as the increasing incidence of chronic inflammation, arthritis, and autoimmune conditions. In addition to that, there has been an increase in the need for innovative pain management methods.
U.S. Anti-Inflammatory Drugs Market Insights Forecasts to 2035
- The US Anti-Inflammatory Drugs Market Size Was Estimated at USD 41.8 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 6.82% from 2025 to 2035
- The US Anti-Inflammatory Drugs Market Size is Expected to Reach USD 80.7 Billion by 2035
Notable Insights for U.S. Anti-Inflammatory Drugs Market
- By drug class, nonsteroidal anti-inflammatory drugs (NSAIDs) accounted for nearly 38.6% share of the United States anti-inflammatory drugs market in 2025.
- Based on assessments linked to the National Institutes of Health, biologic anti-inflammatory therapy adoption across rheumatoid arthritis and autoimmune disease treatment programs increased by approximately 14.7% during 2025, driven by expanding clinical efficacy and precision medicine advancements.
- According to estimates published by the Centers for Disease Control and Prevention, approximately 58.5 Million adults in the United States were diagnosed with arthritis-related conditions in 2025, while inflammatory disease-related healthcare expenditure increased by nearly 11.3% compared with the previous year.
Download the eBook (ToC)
- The United States represented nearly 43% of North America’s immunology and anti-inflammatory pharmaceutical revenues in 2025, reinforcing the country’s leadership position within the global inflammatory therapeutics and specialty biologics ecosystem.
What Makes Decisions Advisors Research Unique?
- Immunology Market Intelligence and Pharmaceutical Forecasting
Decisions Advisors delivers specialized healthcare market intelligence through comprehensive evaluation of inflammatory disease prevalence trends, biologic therapy adoption, chronic pain management technologies, immunology drug pipelines, and specialty pharmaceutical manufacturing developments.
- Advanced Healthcare Research Methodology and Regulatory Validation
Our analytical methodology integrates physician interviews, hospital procurement assessments, FDA regulatory evaluations, pharmaceutical pipeline tracking, healthcare expenditure analysis, and secondary clinical benchmarking to generate highly accurate market forecasts and strategic business intelligence.
- Anti-Inflammatory Drug Innovation Benchmarking and Competitive Landscape Analysis
The study provides a comprehensive analysis of NSAIDs, corticosteroids, biologic anti-inflammatory drugs, monoclonal antibody therapies, cytokine inhibitors, and targeted immunology treatments. Additionally, Decisions Advisors evaluates pharmaceutical R&D investments, clinical trial expansion initiatives, immunotherapy partnerships, and next-generation inflammatory disease treatment technologies to help organizations understand competitive positioning and future market potential within the U.S. anti-inflammatory drugs market.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the US Anti-Inflammatory Drugs market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United States Anti-Inflammatory Drugs Market
- Pfizer Inc.
- AbbVie Inc.
- Johnson & Johnson
- Amgen Inc.
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Novartis AG
- Merck & Co. Inc.
- Sanofi S.A.
- GlaxoSmithKline plc
- Others
Recent Developments:
- In February 2026, AbbVie Inc. invested approximately USD 620 Million toward the expansion of immunology and inflammatory disease research programs in the United States, strengthening the development of next-generation biologic therapies for rheumatoid arthritis and autoimmune disorders.
- In October 2025, Pfizer Inc. received expanded regulatory approval for an advanced anti-inflammatory therapy targeting chronic autoimmune conditions, supporting approximately 16% improvement in clinical response outcomes during late-stage treatment evaluations.
Market Segmentation:
United States Anti-Inflammatory Drugs Market, By Drug Class
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Corticosteroids
- Biologics
- Antihistamines
- Immunosuppressants
- Others
United States Anti-Inflammatory Drugs Market, By Application
- Arthritis
- Respiratory Diseases
- Inflammatory Bowel Disease
- Dermatology Disorders
- Autoimmune Diseases
United States Anti-Inflammatory Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
Expert Views:
As per the observations made by healthcare experts, the U.S. market for anti-inflammatory drugs is anticipated to experience sustainable growth owing to the growing number of chronic inflammatory diseases and increased usage of biological medications along with substantial investments in drug development with a focus on immunology. Monoclonal antibodies, cytokine inhibitors, and advanced precision immunology drugs have been cited as key strategies in the pharmaceutical industry.
Author: Sanket and Pranali By Spherical Insights and Consulting